Pedro Tofani Saint’ana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Tofani Saint’ana has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Morelle
Thummi Global, Porto Alegre, Brazil
21 shared publications - Brenda Rigatti
Department of Oncology, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil
21 shared publications - Rafael Dal Ponte Ferreira
Hospital Moinhos de Vento, Porto Alegre, Brazil
21 shared publications - Alessandro Leal
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
20 shared publications - David Queiroz Muniz
Genitourinary Medical Oncology Service, Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo, São Paulo, Brazil
20 shared publications - Diogo Assed Bastos
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
20 shared publications
Latest Publications
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2C from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 2C: KM curve of OS by TMB
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2C from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 2C: KM curve of OS by TMB
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Study Participants1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Representativeness of Study Participants
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessStudy Participants1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Representativeness of Study Participants
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 4B: KM curve of rPFS in patients with and without PD-L1 expression.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 4B: KM curve of rPFS in patients with and without PD-L1 expression.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Table 2: Oncogenic or Likely Oncogenic DRD genomic alterations found in ctDNA and/or WES
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Table 2: Oncogenic or Likely Oncogenic DRD genomic alterations found in ctDNA and/or WES
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3A from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 3A: KM curve of PSA-PFS in patients with and without DRD.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3A from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 3A: KM curve of PSA-PFS in patients with and without DRD.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Purpose:Despite the success of immune checkpoint inhibitors (ICI) across various cancers, their efficacy in metastatic castration-resistant prostate cancer (mCRPC) is modest, except for a subset of patients who experience significant, yet unpredictable, benefits. DNA repair defects (DRD) are associated with higher neoantigen load, which may predict response. Our study explored the potential of DRD for enhanced responsiveness to the ICI nivolumab.Patients and Methods:We conducted a phase II, multicenter, single-arm trial evaluating nivolumab in patients with mCRPC with prior docetaxel therapy. The DRD were assessed using ctDNA. The primary endpoint was PSA50 response. Secondary endpoints included the objective response rate, radiographic progression-free survival (rPFS), and overall survival. Also, exploratory comprehensive genomic profiling was performed via whole-exome sequencing of tumor samples and matched normal tissues, alongside PD-L1 expression evaluation.Results:Among the 38 enrolled patients, DRD was identifiable in 30.5% (11/36) through ctDNA and/or whole-exome sequencing analyses. The overall PSA50 response rate was 10.5% (4/38). The PSA50 and objective response rates did not significantly differ between patients with and without DRD (18.2% vs. 8%; P = 0.57 and 50% vs. 17.6%; P = 0.27, respectively). The median PSA-PFS (1.9 vs. 2.8 months; P = 0.52) and rPFS (3.4 vs. 5.5 months; P = 0.7) were not statistically different between patients with and without DRD. Grade ≥ 3 adverse events were reported in 47.3% of participants.Conclusions:Nivolumab has clinical activity in a subset of patients with mCRPC; however, DRD does not predict response. These results highlight the necessity of identifying new biomarkers to more accurately determine patients with mCRPC who might respond to ICIs.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Purpose:Despite the success of immune checkpoint inhibitors (ICI) across various cancers, their efficacy in metastatic castration-resistant prostate cancer (mCRPC) is modest, except for a subset of patients who experience significant, yet unpredictable, benefits. DNA repair defects (DRD) are associated with higher neoantigen load, which may predict response. Our study explored the potential of DRD for enhanced responsiveness to the ICI nivolumab.Patients and Methods:We conducted a phase II, multicenter, single-arm trial evaluating nivolumab in patients with mCRPC with prior docetaxel therapy. The DRD were assessed using ctDNA. The primary endpoint was PSA50 response. Secondary endpoints included the objective response rate, radiographic progression-free survival (rPFS), and overall survival. Also, exploratory comprehensive genomic profiling was performed via whole-exome sequencing of tumor samples and matched normal tissues, alongside PD-L1 expression evaluation.Results:Among the 38 enrolled patients, DRD was identifiable in 30.5% (11/36) through ctDNA and/or whole-exome sequencing analyses. The overall PSA50 response rate was 10.5% (4/38). The PSA50 and objective response rates did not significantly differ between patients with and without DRD (18.2% vs. 8%; P = 0.57 and 50% vs. 17.6%; P = 0.27, respectively). The median PSA-PFS (1.9 vs. 2.8 months; P = 0.52) and rPFS (3.4 vs. 5.5 months; P = 0.7) were not statistically different between patients with and without DRD. Grade ≥ 3 adverse events were reported in 47.3% of participants.Conclusions:Nivolumab has clinical activity in a subset of patients with mCRPC; however, DRD does not predict response. These results highlight the necessity of identifying new biomarkers to more accurately determine patients with mCRPC who might respond to ICIs.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 1: Consort Diagram for Genomic Analysis
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 1: Consort Diagram for Genomic Analysis
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 3B: KM curve of rPFS in patients with and without DRD.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3B from Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects
Supplementary Figure 3B: KM curve of rPFS in patients with and without DRD.